Financing Is Improving, But Cell And Gene Therapy Firms May Be Last To Feel It
Investors Are Focused On Less Complex Modalities
ARM’s Cell and Gene Meeting on the Mesa offered optimism that a biopharma financial market recovery is under way, but cell and gene therapies still are seen as risky investments.
